When InnoCan Pharma shareholders gather on August 17, 2026, they won’t just be voting on a new corporate identity β they’ll be weighing in on the company’s financial strategy for the foreseeable future. The proposed name change to Velsa Corp. arrives at a delicate moment, with the biotech firm having recently shelved its ambitions for a US exchange listing.
The Consumer Engine Keeps Running
The company’s most reliable source of strength sits in its wellness division. B.I. Sky Global, the subsidiary behind the Valitic skincare brand, has now surpassed 100,000 positive verified customer reviews across major US marketplaces β a milestone reached just this week. That consumer base, which crossed the two-million-customer threshold earlier this year, provides InnoCan with steady, high-margin revenue while its pharmaceutical arm burns through research capital.
The first quarter of 2026 illustrates the dynamic clearly. Revenue reached 6.465 million US dollars, up 29.7 percent from the final quarter of 2025, with gross margins holding at a formidable 91.1 percent. For the full year 2025, the company reported 26.6 million US dollars in revenue at an 89.9 percent margin.
Pipeline Progress and Regulatory Tailwinds
On the pharma side, the LPT-CBD platform has been accumulating quiet wins. The FDA has assigned an INAD number to the veterinary application and waived fees on multiple occasions β indications that regulators view the technology as genuinely innovative. In the human health arena, the agency has signed off on a non-clinical development plan, and the potential 505(b)(2) regulatory pathway could substantially reduce both the timeline and cost of commercialization. Peer-reviewed studies have demonstrated sustained drug release in animal models, a finding that could underpin future human trials.
The Bear Case: Burn Rate and a Restless Shareholder Base
Yet the gap between canine pain management results and human clinical efficacy remains a chasm that many biotech companies never cross. The pharma division generates no revenue, leaving the company dependent on its “wellness-to-pharma” model to fund research. Should Valitic’s growth stall or marketing costs escalate in the fiercely competitive US skincare market, InnoCan would need to seek additional financing β as evidenced by the recent non-convertible bond provided by major shareholder Tamar Innovest.
Should investors sell immediately? Or is it worth buying InnoCan Pharma?
The shareholder structure adds another layer of fragility. With approximately 82.99 percent of shares held by retail investors, the stock is prone to sharp swings on relatively minor news. The postponed US listing has removed a catalyst many investors were banking on, and without fresh operational milestones, the shares could face a prolonged sideways drift or further downside pressure.
Chart Position and Key Dates
The stock closed Friday, August 7, at 1.50 euros on both the Hamburg exchange and Tradegate, up 1.69 percent on the day. That price sits far from the 52-week high of 12.48 euros reached in October 2025, with the shares currently trading between a support level established in July and resistance near 1.70 euros. The twelve-month trading range β from 1.335 euros to 12.48 euros β underscores just how volatile this title has been.
Two dates now dominate the calendar. The August 17 shareholder meeting, where votes by proxy must be submitted by August 13, represents the most immediate catalyst. Then, on August 31, the company is expected β though not yet confirmed β to release its second-quarter 2026 results, which will reveal whether the growth momentum from Q1 has persisted through the summer.
What the Vote Really Decides
The rebranding to Velsa Corp. is more than cosmetic. It signals an attempt to present a unified profile across biotech and health sectors, potentially positioning the company for a future institutional audience. If shareholders approve the change and the wellness division maintains gross margins above 89 percent, the move could be interpreted as a step toward institutional maturity β and, eventually, a renewed push for that US listing.
Should the vote fail, or should sequential revenue growth decelerate in the coming quarters, the stock would lose one of its few remaining short-term catalysts. Either way, August 17 marks a genuine fork in the road for a company trying to finance ambitious pharmaceutical research on the back of a skincare brand’s success.
Ad
InnoCan Pharma Stock: Buy or Sell?! New InnoCan Pharma Analysis from August 8 delivers the answer:
The latest InnoCan Pharma figures speak for themselves: Urgent action needed for InnoCan Pharma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 8.
InnoCan Pharma: Buy or sell? Read more here...
